天茂集团(000627) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥18,214,993,909.49, representing a 42.77% increase compared to ¥12,758,043,222.03 in the same period last year[2] - Net profit attributable to shareholders decreased by 34.39% to ¥147,295,418.16 from ¥224,513,645.89 year-on-year[2] - The total cost of operations was CNY 18,033,645,549.27, an increase of 45.8% from CNY 12,393,102,598.31 in the same period last year[19] - The company reported a significant increase in insurance business income, which totaled CNY 15,197,146,174.61, compared to CNY 10,306,902,305.05 in Q1 2021[19] - The company's other comprehensive income after tax was CNY -2,118,441,387.55, compared to CNY 302,472,180.87 in the previous year[20] - Total comprehensive income for the period was -1,838,985,806.63, a decrease compared to 733,822,556.50 in the previous period[23] Cash Flow - The net cash flow from operating activities was negative at -¥4,177,736,563.92, a decline of 347.94% compared to ¥1,684,990,698.61 in the previous year[2] - Cash inflow from operating activities totaled 15,653,847,284.40, up from 10,876,318,688.36 in the previous period[25] - Cash outflow from operating activities surged by 115.76% to ¥19,831,583,848.32 from ¥9,191,327,989.75 year-on-year, primarily due to increased policy term factors and higher refunds[7] - Cash inflow from investment activities reached 31,730,670,908.20, significantly higher than 11,541,875,315.22 in the previous period[25] - Net cash flow from investment activities was -47,345,046.67, compared to -4,902,127,375.90 in the previous period[25] - Cash inflow from financing activities amounted to 7,615,766,000.00, an increase from 4,425,001,000.00 in the previous period[26] - Net cash flow from financing activities was 7,541,147,881.15, compared to 4,399,698,437.32 in the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥268,599,951,368.02, an increase of 1.78% from ¥263,903,965,776.01 at the end of the previous year[2] - Total liabilities increased to CNY 232,964,258,490.32, up from CNY 226,429,287,091.68 year-over-year[18] - The total current assets increased to 53,394,775,801.93 from 50,358,426,062.72 at the beginning of the year[16] - Cash and cash equivalents at the end of the period were 26,562,719,974.89, up from 23,250,296,395.01 at the beginning of the year[15] - Other receivables increased to 10,331,996,556.92 from 8,017,804,672.96 at the beginning of the year[15] - The total liabilities include a sell-back financial asset amounting to 16,983,374,000.00, up from 9,425,768,000.00 at the beginning of the year[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 80,635[8] - New Li Yi Group Limited holds 44.56% of shares, totaling 2,201,658,177 shares, with 955,440,000 shares pledged[8] - Wang Wei owns 11.25% of shares, amounting to 555,604,700 shares, with 102,000,000 shares pledged[8] - Liu Yiqian holds 10.47% of shares, totaling 517,500,000 shares, with 116,000,000 shares pledged[8] Earnings Per Share - The basic earnings per share fell by 33.92% to ¥0.03 from ¥0.0454 in the same period last year[2] - Basic and diluted earnings per share were both 0.03, compared to 0.0454 in the previous period[23]

Biocause Pharma-天茂集团(000627) - 2022 Q1 - 季度财报 - Reportify